Ben F.

In 1991, EMED was founded with a mission to revolutionize subcutaneous drug delivery through advanced infusion technology. By combining precision engineering with cutting-edge automation, we have set the standard for high-quality, patient-centric infusion systems. Our commitment to innovation has driven the development of industry-leading infusion pumps, accessories, and complete drug delivery ecosystems ensuring safe, efficient, and reliable drug delivery. Today, EMED’s solutions support patients and healthcare providers in over 37 countries around the globe, enhancing treatment adherence, and optimizing therapeutic outcomes.

Start-up sales division. Responsible for sales of neurovascular procedural products to Neurosurgery, Interventional Neurology, and Interventional Neuroradiology.

Start-up Company manufacturing Cesium 131 radioisotope seeds primarily for prostate cancer, but with additional indications for head, neck, and lung malignancies. Perspective is also developing proprietary alpha-particle radiopharmaceuticals (Theranostics) for targeting cancer from the inside out. Responsible for sales of Cesium 131 to Radiation Oncology and Urology in the Western U.S. market, including Alaska and Hawaii, for LDR Brachytherapy applications

Start-up Company with only FDA-Approved Peripheral Vascular Balloon Microcatheter for Pressure- Directed Embolotherapy. U.S. Launch: March 2017 Responsible for rebuilding and leading the sales organization. Present to Board of Directors. P & L Management. Responsible for hiring, training, developing, coaching, motivating, and optimizing performance of clinical specialists, sales reps, and sales management roles. Responsible for formulating and refining a sales process. Created new sales compensation plan.

Start-up sales division. Responsible for sales and program development of CSI Coronary Atherectomy system in qualified Top-C200 Heart Centers prior to Medicare Product Reimbursement. Responsible for driving disruptive technology and building new physician protocol and referral system. Responsible for selection, training, and FDA-mandated Proctoring of Interventional Cardiologists. Coordinate public relations and media releases with CSI and hospital administration.

Pre-FDA approved Start-up Cardiovascular Device venture. FDA Approval October 27, 2011. Responsible for product launch and commercialization. Responsible for driving disruptive technology, expanding product applications, leading program development, educating referring physicians, changing physician protocol and patient treatment plans. Responsible for formulating and refining a sales process. Responsible for building and leading the sales organization, creating a sales training program, sales and marketing materials, and organizational structure. Responsible for creating a pricing structure, sales compensation program, and assembling a KOL (Key Opinion Leader) physician group. Managed/Coordinated FDA-required Clinical Evaluation (Bench Study) of initial product –The Invisiport

Start-up franchise by acquisition. Responsible for national sales management of Kensey Nash Corporation (KNC) product line. Responsible for Field Sales Training of Spectranetics Vascular Interventions (VI) sales force on KNC product line.

Managed & Led 12 Direct Reports (6 Territory Managers [TM] / 6 Clinical Sales Specialists [CSS]) from Kansas City, MO to San Francisco, CA with a Start-Up sales division responsible for Sales of novel Endovascular devices for the treatment of occlusive disease to Interventional Cardiology (IC), Interventional Radiology (IR), and Vascular Surgery (VS).

Start-up division. Evaluated, Trained, Developed & Mentored new Territory Managers (TM) – Responsible for 6 TMs. Responsible for sales of novel endovascular systems: Stents and PTA Ballons to Interventional Cardiolgy, Interventional Radiology, and Vascular Surgery. Recruited as part of 1st Group of TMs to sell products of, and help build and develop the Start-Up Endovascular Technologies Division of Edwards Lifesciences

Responsible for selling endovascular systems: Stents, PTA Balloons, Guides, Diagnostic Caths, Guidewires, and Thrombus Management devices to Interventional Radiology, Interventional Cardiology, and Vascular Surgery